Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/15 10:39:56 am
516.095 USD   -0.35%
01/13S&P closes higher with defensive sectors leading gains
RE
01/13Wall St gains steadily while impeachment hearings get underway
RE
01/13SECTOR UPDATE : Health Care Stocks Trading Lower Premarket Wednesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Regeneron Pharmaceuticals : FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug

11/21/2020 | 08:28pm EST

By Joseph Walker

Regeneron Pharmaceuticals Inc.'s Covid-19 antibody drug was authorized Saturday by U.S. health regulators, the second cleared this month to treat patients who aren't hospitalized but are at high risk of developing severe disease.

The FDA cleared the antibody drug cocktail for use treating mild to moderate Covid-19 patients 12 years of age and older, including people older than 65 years.

Regeneron's drug combines two lab-made antibodies designed to latch onto the novel coronavirus and prevent it from replicating and hijacking human cells. The treatment is still being tested in clinical trials, after being developed by Regeneron scientists in Tarrytown, N.Y., earlier this year.

In October, it was one of three pharmaceutical treatments given to President Trump for treatment of Covid-19, and which Mr. Trump later attributed his recovery. "They gave me Regeneron, and it was like, unbelievable. I felt good immediately," he said.

The U.S. Food and Drug Administration said it authorized the drug's emergency use, a kind of clearance the agency has been using during the pandemic to speed up access to medicines.

The FDA said its authorization was based on a study of about 800 people. In the study, 3% of subjects taking Regeneron's drug and who were at high risk of severe disease had to be hospitalized or visit emergency rooms, compared with 9% of patients who received a placebo.

"The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic," Patrizia Cavazzoni, M.D., acting director of the FDA's Center for Drug Evaluation and Research, said in a statement.

Earlier this month, the FDA issued an emergency authorization for antibody drug made by Eli Lilly & Co. for a similar set of patients.

Write to Joseph Walker at joseph.walker@wsj.com

(END) Dow Jones Newswires

11-21-20 2027ET

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 0.20% 187.39 Delayed Quote.10.57%
REGENERON PHARMACEUTICALS -0.70% 513.16 Delayed Quote.7.20%
All news about REGENERON PHARMACEUTICALS
01/13S&P closes higher with defensive sectors leading gains
RE
01/13Wall St gains steadily while impeachment hearings get underway
RE
01/13SECTOR UPDATE : Health Care Stocks Trading Lower Premarket Wednesday
MT
01/13REGENERON PHARMACEUTICALS : Benchmark Upgrades Regeneron Pharmaceuticals to Buy ..
MT
01/13TIZIANA LIFE SCIENCES : Names Chief Medical Officer
MT
01/13TIZIANA LIFE SCIENCES : Science Appoints New Chief Medial Officer; Shares Up 13%
MT
01/12REGENERON PHARMACEUTICALS : to Supply U.S. Government with up to 1.25 Million Do..
MT
01/12REGENERON PHARMACEUTICALS : U.S. to buy 1.25 mln additional doses of Regeneron's..
RE
01/12REGENERON PHARMACEUTICALS : U.S. government to buy 1.25 mln additional doses of ..
RE
01/12REGENERON PHARMACEUTICALS : Announces U.S. Government Agreement to Purchase Addi..
PR
More news
Financials (USD)
Sales 2020 8 543 M - -
Net income 2020 3 178 M - -
Net cash 2020 5 480 M - -
P/E ratio 2020 18,5x
Yield 2020 -
Capitalization 54 663 M 54 663 M -
EV / Sales 2020 5,76x
EV / Sales 2021 4,35x
Nbr of Employees 8 314
Free-Float 83,1%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 657,81 $
Last Close Price 517,91 $
Spread / Highest target 53,1%
Spread / Average Target 27,0%
Spread / Lowest Target -3,46%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS7.20%54 663
GILEAD SCIENCES, INC.7.11%78 220
VERTEX PHARMACEUTICALS-4.32%58 800
WUXI APPTEC CO., LTD.5.37%53 415
BEIGENE, LTD.30.02%30 634
GENMAB A/S8.08%28 435